Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis
Prior rituximab treatment appears to be protective against inflammatory activity after AHSCT. Disease duration and gadolinium-enhancing lesions are major determinants of disability following AHSCT.
Authors
- Christina Zjukovskaja (ORCID: https://orcid.org/0000-0003-0934-4478)
- Andreas Tolf (ORCID: https://orcid.org/0000-0002-0580-8821)
- Yassine Noui (ORCID: https://orcid.org/0000-0002-0513-7546)
- Thomas Silfverberg (ORCID: https://orcid.org/0000-0002-3829-285X)
- Kristina Carlson (ORCID: https://orcid.org/0000-0002-0303-1350)
- Kim Kultima (ORCID: https://orcid.org/0000-0002-0680-1410)
- Per Ljungman (ORCID: https://orcid.org/0000-0002-8281-3245)
- Joachim Burman (ORCID: https://orcid.org/0000-0002-7045-1806)
- Tobias Tolf
Institutions
- Uppsala University (SE)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Center for Clinical Research Dalarna (SE)
Publication Details
- Journal
- Journal of Neurology Neurosurgery & Psychiatry
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1136/jnnp-2024-335512
- Citations
- 4
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.89
Funders
- Svenska Sällskapet för Medicinsk Forskning
- Vetenskapsrådet
- Svenska Läkaresällskapet
- Marcus och Amalia Wallenbergs minnesfond